C
Cybin Inc
AMEX:CYBN
Cybin Inc
AMEX:CYBN
Price:
5.86
USD
-7.86%
Market Cap:
$4.5B
Relative Value
There is not enough data to reliably calculate the relative value of CYBN.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
CYBN
Relative Value
Base Case
Not Available
Multiples Across Competitors
CYBN Competitors Multiples
Cybin Inc Competitors
Cybin Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CA |
C
|
Cybin Inc
AMEX:CYBN
|
4.5B USD | 0 | -49.5 | -40.9 | -40.8 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
995.7B USD | 15.3 | 48.2 | 32.5 | 34.5 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
573.2B USD | 6.1 | 21.5 | 15 | 18.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
281.7B CHF | 4.6 | 30 | 12.7 | 14.8 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
300.5B USD | 4.7 | 16.7 | 10.4 | 12.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
231.3B CHF | 5.3 | 21.2 | 13.1 | 16.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
217.3B GBP | 5.2 | 31.9 | 15.2 | 22.2 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 333.1 | 835.4 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.3T DKK | 4.2 | 12.7 | 9.3 | 11 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153B USD | 2.5 | 19.8 | 7.4 | 9.9 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
125.7B USD | 2.6 | 20.6 | 7.3 | 9.5 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
